# First-line Olaparib Combined With Bevacizumab Maintenance Therapy

> **NCT05440578** · — · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** olaparib plus bevacizumab maintenance therapy

## Key facts

- **NCT ID:** NCT05440578
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2022-09
- **Final completion:** 2022-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05440578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05440578, "First-line Olaparib Combined With Bevacizumab Maintenance Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05440578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*